Skillman, NJ - November 4, 2024 - Kenvue Inc. today announced the appointment of Andrew Stanleick to the role of President, Skin Health & Beauty for North America and Europe, Middle East and Africa, leading the strategic direction of our iconic portfolio of brands, including Neutrogena®, Aveeno® and OGX®, in the regions.

"We are very pleased to have Andrew join Kenvue in this critical role," said Charmaine England, Chief Growth Officer, Kenvue. "With over two decades of experience in leading the profitable growth and omni-channel transformation of global multi-brand portfolios in skin health, beauty, and fashion, Andrew brings a proven track-record of success and deep industry knowledge to strengthen the growth trajectory of our Skin Health & Beauty segment in key markets."

"I am thrilled to join the Kenvue team at such an exciting time for the Company," said Andrew Stanleick. "As a global leader in consumer health, Kenvue's iconic skin health and beauty brands have been trusted by consumers and recommended by healthcare professionals for generations. I look forward to helping these brands reach more consumers in new ways in 2025 and beyond."

Prior to joining Kenvue, Andrew served as the President and CEO of BeautyHealth Company (NASDAQ: SKIN), a global category-creator in skin health known for its flagship brand, HydraFacialTM. During his tenure, Andrew led the business to profitability in one-year, growing revenue by over 50%, expanding the company's global footprint, and improving brand awareness via strategic partnerships with celebrities, brands and retailers. Before joining BeautyHealth, he served as the Executive Vice President of Coty Americas, overseeing their portfolio of Luxury and Consumer brands across the region. In this role, Andrew led the successful turnaround and profitable growth transformation of this multi-billion-dollar annual sales region for Coty, including its flagship beauty brand, COVERGIRL®. Notably, Andrew also served as the Global CEO for the joint venture with Kylie Jenner Beauty and oversaw the Kim Kardashian business. Earlier in his career, Andrew spent several years as President and CEO of Coach Inc., Europe and South Asia & Pacific as well as held senior marketing and country management leadership roles across multiple channels and categories at Unilever and L'Oreal.

About Kenvue

Kenvue is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe in the extraordinary power of everyday care and our teams work every day to put that power in consumers' hands and earn a place in their hearts and homes. Learn more at www.kenvue.com.

Cautions Concerning Forward-Looking Statements

This alert contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the appointment of Andrew Stanleick to the role of President, Skin Health & Beauty for North America and Europe, Middle East and Africa at Kenvue. Forward-looking statements may be identified by the use of words such as "plans," "expects," "will," "anticipates," "estimates" and other words of similar meaning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kenvue and its affiliates. A list and descriptions of these risks, uncertainties and other factors can be found in Kenvue's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q and other filings, available at www.kenvue.comor on request from Kenvue. Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise.

Attachments

  • Original document
  • Permalink

Disclaimer

Kenvue Inc. published this content on November 05, 2024, and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on November 05, 2024 at 17:18:01.749.